Home LiteratureArticle Details
PMID: 10816523 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Antibody interactions with the capsule of Cryptococcus neoformans.

Infection and immunity ·Vol. 68 ·No. 6 ·2000-06-00 ·Pages 3642-50

Feldmesser M, Rivera J, Kress Y, Kozel TR, Casadevall A

Abstract

Monoclonal antibodies to the encapsulated fungus Cryptococcus neoformans produce different immunofluorescence (IF) patterns after binding to the polysaccharide capsule. To explore the relationship between the IF pattern and the location of antibody binding, two immunoglobulin M (IgM) monoclonal antibodies (MAbs) (12A1 and 13F1) that differ in protective efficacy and IF pattern and one protective IgG1 MAb (2H1) were studied by IF and electron microscopy (EM). Fixing C. neoformans cells in lung tissue for EM resulted in significantly better preservation of the capsule than fixing yeast cells in suspension. The localization of MAbs 12A1 and 13F1 by immunogold EM differed depending on whether the MAb was bound to cells in cut tissue sections embedded in plastic or to cells in solution. In cut tissue sections, MAbs 12A1 and 13F1 bound throughout the capsule, whereas in solution both MAbs bound near the capsule surface. To investigate whether antibody binding to the C. neoformans capsule affected the binding of other primary or secondary reagents, various combinations of MAbs 12A1, 13F1, and 2H1 were studied by direct and indirect IF. The IF pattern and location of binding for MAbs 12A1, 13F1, and 2H1 varied depending on the presence of other capsule-binding MAbs and the method of detection. The results show that (i) binding of MAbs to the C. neoformans polysaccharide capsule can modify the binding of subsequent primary or secondary antibodies; (ii) the IgM MAbs bind primarily to the outer capsule regions despite the occurrence of their epitopes throughout the capsule; and (iii) MAb 2H1 staining of newly formed buds is reduced, suggesting quantitative or qualitative differences in bud capsule.

MeSH Terms
Animals Antibodies, Fungal/immunology Antibodies, Monoclonal Binding Sites Cell Wall/immunology,ultrastructure Cryptococcosis/microbiology Cryptococcus neoformans/immunology,ultrastructure Gold Immunoglobulin M Mice Mice, Inbred C57BL Microscopy, Immunoelectron Polysaccharides/immunology,ultrastructure
Chemicals
Antibodies, Fungal Antibodies, Monoclonal Immunoglobulin M Polysaccharides Gold
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Feldmesser M
Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Rivera J
Kress Y
Kozel T R
Casadevall A
References (37)
37 references, click to expand
  1. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
    Infect Immun. 1989 Dec;57(12):3882-7 PMID: 2680986
  2. A rapid fluorescent assay to distinguish attached from phagocytized yeast particles.
    J Immunol Methods. 1987 Jul 16;101(1):37-42 PMID: 3112238
  3. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.
    Infect Immun. 1990 Jun;58(6):1914-8 PMID: 2187813
  4. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    J Infect Dis. 1992 Jun;165(6):1086-93 PMID: 1583327
  5. Regulation of cryptococcal capsular polysaccharide by iron.
    J Infect Dis. 1993 Jan;167(1):186-90 PMID: 8418165
  6. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.
    J Exp Med. 1993 Apr 1;177(4):1105-16 PMID: 8459205
  7. Ultrastructural study of Cryptococcus neoformans by quick-freezing and deep-etching method.
    Mycopathologia. 1993 Mar;121(3):133-41 PMID: 8474529
  8. Ultrastructural study of hepatic granulomas induced by Cryptococcus neoformans by quick-freezing and deep-etching method.
    Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(1):57-66 PMID: 8401817
  9. Polysaccharide antigens of the capsule of Cryptococcus neoformans.
    Infect Immun. 1994 May;62(5):1507-12 PMID: 8168912
  10. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
    Infect Immun. 1994 Sep;62(9):3864-72 PMID: 8063403
  11. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
    J Exp Med. 1995 Jan 1;181(1):405-9 PMID: 7807020
  12. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
    Infect Immun. 1995 Aug;63(8):3005-14 PMID: 7622223
  13. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins.
    J Infect Dis. 1996 May;173(5):1222-31 PMID: 8627076
  14. Activation of the complement system by pathogenic fungi.
    Clin Microbiol Rev. 1996 Jan;9(1):34-46 PMID: 8665475
  15. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
    J Mol Biol. 1996 Aug 9;261(1):11-22 PMID: 8760499
  16. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group.
    Clin Infect Dis. 1996 Jul;23(1):82-90 PMID: 8816134
  17. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
    Zentralbl Bakteriol. 1996 Aug;284(4):475-95 PMID: 8899968
  18. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.
    J Immunol. 1997 Jan 15;158(2):790-9 PMID: 8992996
  19. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
    J Exp Med. 1997 Feb 17;185(4):685-94 PMID: 9034147
  20. Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro.
    Infect Immun. 1997 May;65(5):1899-907 PMID: 9125578
  21. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.
    Infect Immun. 1998 Mar;66(3):1244-7 PMID: 9488420
  22. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.
    Clin Diagn Lab Immunol. 1998 Mar;5(2):125-9 PMID: 9521132
  23. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.
    Infect Immun. 1998 Apr;66(4):1538-46 PMID: 9529079
  24. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity.
    Res Immunol. 1998 May-Jun;149(4-5):321-33; discussion 500-3 PMID: 9720950
  25. Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection.
    Infect Immun. 1998 Oct;66(10):5027-30 PMID: 9746613
  26. Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release.
    Med Mycol. 1999 Aug;37(4):235-43 PMID: 10421858
  27. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody.
    Infect Immun. 1999 Sep;67(9):4620-7 PMID: 10456908
  28. Monoclonal antibody 13F1 produces annular immunofluorescence patterns on Cryptococcus neoformans serotype AD isolates.
    J Clin Microbiol. 1999 Sep;37(9):3080 PMID: 10475750
  29. Capsule synthesis by Cryptococcus neoformans.
    Trans N Y Acad Sci. 1958 May;20(7):623-48 PMID: 13556861
  30. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.
    Front Biosci. 1998 Feb 1;3:d136-51 PMID: 9445465
  31. Micromorphology of Cryptococcus neoformans.
    J Bacteriol. 1967 Sep;94(3):766-77 PMID: 6035270
  32. The ultrastructure of Cryptococcus neoformans.
    Sabouraudia. 1971 Jul;9(2):115-8 PMID: 4106826
  33. Genetic control of susceptibility to Cryptococcus neoformans in mice.
    Infect Immun. 1980 Aug;29(2):494-9 PMID: 7216421
  34. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.
    J Clin Invest. 1985 Aug;76(2):508-16 PMID: 3928681
  35. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.
    Infect Immun. 1987 Mar;55(3):742-8 PMID: 3546139
  36. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
    Infect Immun. 1987 Aug;55(8):1895-9 PMID: 2440810
  37. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
    Mol Cell Probes. 1989 Dec;3(4):345-61 PMID: 2482437
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
Published
2000-06-00
Pages
3642-50
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC97654
Subset
IM
Grants
NIAID NIH HHS · R01 AI033774 · United States
NHLBI NIH HHS · R01 HL059842 · United States
NIGMS NIH HHS · F31 GM018951 · United States
NIAID NIH HHS · K08AI01341 · United States
NIGMS NIH HHS · 5-F31-GM18951 · United States
NIAID NIH HHS · R01 AI014209 · United States
NIAID NIH HHS · R01-AI14209 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]